As a large number of new drugs for β-amyloid clearance in AD showed limited efficiency in halting disease progression in clinical trials, tau protein attracts increasing attentions as a new therapeutic target.32 For instance, developing drugs to prevent tau translation from mRNA by antisense nucleotides,3 and to promote tau degradation with PROTACs5,6,33 are being carried on. This evidence concerns the gene MAPT and Alzheimer disease.